Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

Background Mutant isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a targeted mutant IDH1 inhibitor under evaluation in a phase 1 dose escalation and expansion study of IDH1-mutant advanced solid tumors including chol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Fan, Bin, Mellinghoff, Ingo K., Wen, Patrick Y., Lowery, Maeve A., Goyal, Lipika, Tap, William D., Pandya, Shuchi S., Manyak, Erika, Jiang, Liewen, Liu, Guowen, Nimkar, Tara, Gliser, Camelia, Prahl Judge, Molly, Agresta, Sam, Yang, Hua, Dai, David
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066280/
https://ncbi.nlm.nih.gov/pubmed/31028664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00771-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados